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Abbreviations 
APC: Antigen Presenting Cell 
CMP: Cow’s milk protein 
CT: Cholera toxin 
dNL: Draining lymph node 
EP: Epicutaneous 
EPIT: Epicutaneous Immunotherapy 
HK: Heat-killed 
ID: Intradermal 
IG: Intragastric  
IN: Intranasal 
IP: Intraperitoneal 
IPIT: Intraperitoneal Immunotherapy 
IT: Immunotherapy 
IV: Intravenous 
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SCIT: Subcutaneous immunotherapy 
SLIT: Sublingual IT 
Treg: Regulatory T cell 
 
Abstract 
Food allergy is an adverse reaction to otherwise harmless proteins in food. The 
disease is a major health problem of growing concern, affecting approximately 5-8% of young 
children and 2-4% of adults. No accepted strategy exists for prevention and treatment of food 
allergy, and strict avoidance of the offending food is presently the only viable management option. 
Living with food avoidance may have a huge impact on the quality of life of food allergic patients, 
with daily fear of serious or even fatal reactions. The urgent need for safe and efficient food allergy 
treatment options has led to massive research efforts to develop and improve strategies for food 
allergy immunotherapeutic approaches. A first step in developing new and improved strategies of 
immunotherapy often involves the use of animal models. In present review, we provide an overview 
of animal studies of allergen-specific immunotherapy highlighting opportunities and challenges for 
each approach. The presented models, almost exclusively performed in mice, assess therapeutic 
efficacy and immunological outcomes following oral, intraperitoneal, subcutaneous, epicutaneous, 
and sublingual administration of native allergens, or preparations of hydrolyzed allergen, T cell 
directed peptides, or allergen with immunomodulatory adjuvants. Recently, approaches using 
immune cell therapy have demonstrated efficacy. Current models mainly assess anaphylaxis as the 
primary clinical outcome. With the increased appreciation that food allergy is a heterogeneous 
disease presenting different phenotypes, there is a continued need to develop new disease-relevant 
therapeutic models of food allergy. 
 
Introduction 
Food allergy is an immune mediated hypersensitivity to specific proteins in food, 
which occur as a result of allergic sensitization due to a failure of the immune system to develop 
tolerance after first exposure, or the abrogation of an already established tolerance. The prevalence 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
of food allergy is estimated to be around 5-8% in young children and around 2-4% in adults in the 
Western world [1], and appears to be a rising problem [1,2]. Most cases of food allergy is mediated 
by IgE-dependent immediate hypersensitivity reactions, however some rarer food allergies may also 
involve cell-mediated sensitization with and without the contribution of IgE (extensively reviewed in 
[3,4]). Ingestion of disease-triggering foods in sensitized individuals can cause an array of symptoms 
in the gastrointestinal tract (pain, nausea, vomiting and diarrhea), skin (itchiness, urticarial and 
angioedema), respiratory and cardiovascular systems (dyspnea, wheezing, and tachycardia) [5]. In 
severe cases allergic reactions can cause acute respiratory and cardiac arrest. The first line of 
management involves food-avoidance, and acute systemic reactions are treated with epinephrine, 
which are often carried by patients with severe allergy in case of accidental ingestion. The lack of 
treatment options, restrictive food-avoidance, and the prospect of accidental ingestion makes food 
allergy a chronic disease that significantly impacts the quality-of-life for patients [6]. 
 
Allergen-specific immunotherapy (IT) is emerging as a viable option for human 
desensitization with the ability to increase thresholds of reactivity, as demonstrate by a recent 
systematic meta-analysis of 31 clinical trials in food allergy [7]. However, current immunotherapeutic 
regimens are typically lengthy with repeated, increasing doses of allergen, and the risk of acute 
adverse reactions. Furthermore, current regimens are largely unable to induce complete clinical 
tolerance. Thus there is a need to develop better regimens of allergen-specific IT. Testing therapies 
in animal disease models is central to evaluating the potential of new immunotherapeutic strategies 
or modified versions of current regimens. Here we present a comprehensive overview of animal 
models of food allergy therapy currently reported in the literature, and highlight opportunities for 
new avenues of study and model improvements. This review will primarily address IT in animal 
models using allergens and allergen-challenges of relevance to clinical food allergy outcomes. A 
detailed overview of the presented therapeutic animal models can be found in table 1, and 
summarized in figure 1. Currently most models have been developed in mice exploring oral therapy 
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with dosaging of native protein, and to some extent less allergenic preparations containing 
hydrolyzed allergen and immunodominant T cells epitopes. Models using epicutaneous (EPIT) or 
subcutaneous immunotherapy (SCIT) has in recent years received increased attention due to 
possible better safety and efficacy of these routes compared to oral administration. Additionally, 
models exploring therapy using immunomodulatory adjuvants or cell therapy have been developed. 
Current studies have addressed several immunological and clinical outcomes of therapy 
(summarized in figure 2). However, most models only assess the acute anaphylaxis outcome of food 
allergy by temperature loss and clinical severity scoring. With the increased appreciation that food 
allergy is a heterogeneous disease presenting with different phenotypes and mechanisms in relation 
to foods, exposure, symptoms, and natural history [8], there is a continued need to develop new 
disease-relevant therapeutic models in food allergy. 
 
Oral immunotherapy 
 The default outcome of ingesting food is for the immune system to tolerate the 
exposure to the foreign antigens contained within. The concept of oral tolerance has been studied in 
rodents since 1910, with early studies describing how oral ingestion of antigen would inhibit later 
experimental hyperactivity, thus demonstrating that tolerance to ingested food involves active 
antigen-specific suppression of hypersensitivity [9]. Several later studies have addressed the 
mechanistic basis of oral tolerance, including a pivotal role of regulatory T cells (reviewed in [10,11]). 
Oral IT (OIT) models have been developed using egg white [12], ovomucoid (native or heated) [12], 
ovalbumin [13], cow’s milk proteins [14,15] and peanut [15–17] in sensitized mice. In these studies 
therapy were able to reverse or ameliorate food challenge-induced anaphylaxis and clinical disease 
scores, when mice were challenged immediately after treatment. However some studies found 
[12,13,17], that the desensitization was short-term as sensitization returned within 2-5 weeks after 
therapeutic cessation. These findings are in line with oral immunotherapy trials in humans reporting 
limited effects on the induction of sustained unresponsiveness in food allergic individuals. The OIT 
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models found varying effect on the levels of allergen-specific IgG reporting similar [12–14], 
decreased [17], or increased [15] IgG1 levels, and similar [12–14] or increased [13,15,16] IgG2a 
levels. The therapeutic effect on allergen-specific IgE levels were similarly diverse with similar 
[13,15], increased [12] or decreased [14,16,17] levels reported. These findings could be attributed to 
the dynamic nature of Ig levels during IT, and are in line with studies in humans reporting different Ig 
patterns depended on IT efficacy and duration [18,19]. Interestingly, the studies in ovalbumin-
sensitized mice observed sustained systemic allergen-specific humoral immune responses after 
therapy, as demonstrated by basophil activation assays and peritoneal mast cells activation [12,13]. 
Thus the mice was shown to be desensitized when orally challenged with allergen, but anaphylaxis 
could be induced by systemic allergen-challenge [12]. Similar results were observed in another study 
where peanut and whey OIT suppressed mast cell responses following oral challenge, but only mice 
receiving peanut OIT were protected from intraperitoneal (IP) induced anaphylaxis, indicating 
allergen-specific differences in therapeutic outcomes and mechanisms [15]. The therapeutic 
suppression of local gastrointestinal allergic responses was proposed to be mediated by increased 
IgA levels induced by treatment; however this hypothesis remains to be formally investigated [12]. 
Oral therapy was also associated with increased gastrointestinal permeability and changes in 
transcriptional profile in proximal jejunum [12]. The significance of these treatment-induced changes 
remain to be investigated, but may reflect the adverse gastrointestinal effects reported in human 
clinical trials. 
 
Allergen-specific ex vivo production of T cell related type-2 cytokines (IL-4, IL-5 and/or 
IL-13) were suppressed after egg [12], cow’s milk protein [14,15] and peanut [16] OIT, indicating 
suppression of systemic effector T cell immune responses. Indeed the studies found increased 
numbers of CD4+CD25+FoxP3+ regulatory T cells in the intestine or mLN in response to milk protein 
[14,15] or peanut [16] therapy. The induction of intestinal regulatory T cells was associated with 
increased tissue expression of regulatory effector cytokines TGF-β and IL-10 [14]. Unexpectedly, IT in 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
ovalbumin-sensitized mice did not result in the generation of CD4+CD25+FoxP3+ regulatory T cells 
[13], and ex vivo allergen-specific IL-10 was suppressed in mice receiving OIT [12]. These results 
suggest the induction of different immune regulatory mechanisms in the therapeutic response to 
different allergens or regimens. The study using peanut IT [16] found, that the expansion of 
regulatory T cells was abrogated eight weeks post-therapy, and the induced regulatory T cells were 
unable to transfer desensitization to sensitized mice. These findings suggest that the short-term 
desensitization in these models is due to the unstable induction of regulatory T cells. Interestingly, a 
study combining peanut OIT and abrogation of IgE signaling by anti-IgE antibody or Syk inhibitor 
administration in allergy-prone Il4raF709 (gain-of-function mutation in the IL-4 receptor α chain) 
mice found induction of sustained unresponsiveness associated with expansion of regulatory T cells 
and suppression of allergen-specific Th2 cells [17]. These findings are in line with recent studies in 
humans, where anti-IgE can facilitate accelerated desensitization by oral dosing of allergen [20]. 
Combined, the studies presented here suggest that induction of allergen-specific regulatory T cells is 
pivotal for efficient IT of food allergy, and different allergens and therapeutic regimens may induce 
regulatory T cells with different phenotypes. There is a need to study co-administration of immune 
modulatory reagents (TLR agonists and biologicals) in OIT models, and some examples are discussed 
later in the review. 
 
Intraperitoneal immunotherapy 
 The studies presented above performed IT to food proteins via the oral route, 
however a couple of studies have used intraperitoneal (IP) injections with tree nut (cashew and 
walnut) protein extracts as a model of oral therapy [21,22]. Cashew intraperitoneal IT (IPIT) was able 
to abrogate allergic reactions in response to cashew [21] or pistachio [22] (due to cross-reactivity) in 
cashew-sensitized mice. Furthermore, cashew-, walnut- or combined-IT was able to ameliorate 
anaphylaxis (temperature loss) and clinical disease presentation in cashew and walnut dual-
sensitized mice due to cross-reactivity between these three nuts [22]. IT was associated with 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
increased allergen-specific IgG1 [21,22], IgG2 [21] and suppression of T cell related type-2 cytokine 
release (IL-4, IL-5 and IL-13) [21,22] by splenocytes. Interestingly, in these models challenges were 
performed IP 2-5 weeks post-treatment indicating long-term efficacy of therapy. These findings are 
opposed to the studies of OIT reviewed above, in which efficacy to oral challenges was lost 2-4 
weeks post-treatment and allergic reactivity was sustained in response to IP (systemic) challenge for 
ovalbumin and whey OIT [12,15]. This indicates that the therapeutic tolerance induced via the oral 
route is different from tolerance generated via IP allergen administration. It could be speculated that 
oral allergen administration subverts long-term protection by chronic activation of IgE-dependent 
mechanisms, as indicated in the case of oral peanut desensitization in combination with anti-IgE 
[17]. However, more experimental work comparing administration routes using the same allergens, 
sensitization and challenge protocols are required to address this hypothesis. Furthermore, the role 
of regulatory T cells in IPIT models remains to be investigated. 
 
Immunotherapy using hydrolyzed food proteins 
It is generally accepted, that hydrolyzed food allergens exhibit lower allergenicity due 
the destruction of allergenic epitopes. It has been demonstrated, that pepsin-digested cashew 
protein extracts elicit a reduced anaphylactic response (temperature loss and symptom score) 
compared to undigested protein in a murine food allergy model using IP or oral sensitization to 
undigested cashew protein [21]. Both digested and undigested cashew protein were show to have 
similar allergenicity by inducing comparable IgE- and Th2-responses, and clinical anaphylaxis 
following challenge in mice sensitized to the respective preparations using adjuvant. These 
observations demonstrate the principle, that IT using digested protein has reduced potential to elicit 
an allergic response during therapy to native food protein. The study continued to use digested 
cashew protein as IPIT in mice sensitized to undigested cashew protein [21]. IT was demonstrated to 
abrogate anaphylaxis when the mice were challenged with undigested protein. Furthermore, 
therapy was associated with the induction of allergen-specific IgG1 and IgG2a, as well as suppression 
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of IL-5 and IL-13 production by splenocytes. The clinical and immunological outcomes were 
comparable to mice receiving IPIT using undigested protein extract, indicating the same mechanism 
of desensitization. OIT using hydrolyzed egg white proteins in egg white sensitized mice was 
indicated to ameliorate anaphylaxis as demonstrated by normalizing serum histamine levels 
following challenge [23]. Therapy was associated with a modest reduction in allergen-specific IgE 
and IgG2a, whereas IgG1 was unchanged. Allergen-stimulated splenocytes demonstrated reduced 
systemic Th1 (IFN-γ) and Th2 (IL-4) responses. Furthermore, expression of Th1 and Th2 effector 
cytokines (IFN-γ, IL-12p40, IL-4 and IL-13) was reduced in intestinal tissue; however IL-18 and IL-5 
were increased. Therapy was found to promote expression of immune regulatory genes TGF-β and 
FoxP3 but suppress IL-10 in intestinal tissue, suggesting the generation of regulatory T cells in 
therapy using digested allergens. As discuss in previous sections, IPIT and OIT may elicit different 
mode of desensitization, and oral therapy may give rise to specific gut protection and adverse 
reactions depended on the allergen [12,15]. Thus, OIT using digested and undigested protein needs 
to be compared head-to-head to determine altered efficacy, reduced adverse effects and 
mechanism of desensitization.  
 
T cell directed peptide immunotherapy 
 IT using specific peptides may be a more specific alternative to the use of digested or 
hydrolyzed food proteins allowing a consistent and well-defined therapy. Several studies have 
systematically assayed specific peptides from allergens to identify T cell epitopes by the means of 
stimulating immune cells from sensitized animals or allergic patients followed by measuring 
proliferation or cytokine production. Allergen immunodominant T cell epitopes have been identified 
for several food allergens for mice (ovalbumin [24], ovomucoid [25], beta-lactoglobulin [26,27], and 
shrimp tropomyosin [28]) and human (peanut Ara h 1 [29,30] and Ara h 2 [31,32], and shrimp 
tropomyosin [33]). Oral administration of murine immunodominat peptides have been shown to 
ameliorate or reverse anaphylaxis, disease scores and/or diarrhea in mice sensitized to ovalbumin 
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[34], ovomucoid [35], shrimp tropomyosin [28], and beta-lactoglobulin [36]. The studies of 
ovomucoid and beta-lactoglobulin reported a therapeutic effect of single peptide administration (15- 
and 22-mers) [35,36], whereas none of three different peptides (15-mers) in the ovalbumin study 
had an effect when administered individually [34]. However, administration of the three ovalbumin 
peptides as a cocktail significantly ameliorated clinical anaphylactic scores and systemic histamine 
levels, suggesting varying efficacy of different T cell epitopes. The study in shrimp-tropomyosin 
sensitized mice compared a cocktail of six immunodominant and six non-immunodominat peptides 
(20-mers) demonstrating specific efficacy of immunodominant peptide IT [28]. Therapy directed 
against ovalbumin [34], ovomucoid [35] or shrimp-tropomyosin [28] reported decreased allergen-
specific IgE levels and suppression of type-2 immune responses (IL-4, IL-5 and IL-13) in the intestine 
or following ex vivo stimulation. Additionally, these studies found therapeutic induction of immune 
regulatory mechanisms indicated by increased intestinal expression of FoxP3, TGF-β and/or IL-10 
[28,34], as well as increased allergen-specific IL-10 production and systemic CD4+FoxP3+ regulatory T 
cell numbers [35]. The study using peptide IT in beta-lactoglobulin sensitized mice was unable to 
report therapeutic effects on antibody levels (allergen-specific IgE, IgG1, IgG2a, IgA, or total IgE), 
allergen-specific immune responses ex vivo (IL-10, IFN-γ, IL-10, and IL-12), or splenic 
CD4+CD25+FoxP3+ regulatory T cell numbers, suggesting different mode of action or experimental 
difficulties in this study [36]. 
 
OIT using immunodominant peptides show therapeutic potential, but long-term 
efficacy remains to be studied in these pre-clinical models. Unfortunately, recent clinical trials using 
Fel d 1 peptide therapy in humans have been disappointing in terms of therapeutic effect (Circassia 
Pharmaceuticals plc, June 20th 2016 press release, www.circassia.com). This may be attributed to the 
need for immunodominant peptides that could be different among patients due to genetic HLA 
diversity. Indeed, systematic screening reveal different peptide epitopes among different mouse 
stains for ovomucoid [25] and beta-lactoglobulin [26,27]. 
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Subcutaneous immunotherapy 
 Administrating IT via other routes than oral may elicit different clinical and 
immunological outcomes when the food allergy expressing organ is not targeted directly. 
Subcutaneous (SC) injections have for decades been used in IT of allergic disease with demonstrated 
efficacy in asthma, rhinitis, and venom allergies [37]. However, the use of subcutaneous IT (SCIT) in 
food allergy was likely abandoned in the 1990s due to high rates of adverse systemic reactions in 
peanut allergic patients [38,39]. A recent study compared SCIT and OIT in models of cow’s milk 
(whey) and peanut allergy [15]. SCIT and OIT were able to suppress anaphylaxis and mast cell 
degranulation (serum mMCP-1) following intragastric (IG) or intradermal (ID) challenge in both 
models with no clear differences in route-dependent efficacy. Rather, clinical allergen-dependent 
differences were indicated by the observation that neither SCIT nor OIT could protect from IP 
induced anaphylaxis in whey sensitized mice, but peanut sensitized mice were protected in a 
therapeutic dose-dependent manner. Both SCIT and OIT increased serum allergen-specific IgG1 and 
IgG2a, whereas only SCIT increased allergen-specific IgE. This may be in line with the observation, 
that only OIT suppressed (whey) or had similar (peanut) allergen-specific type-2 cytokines 
production (IL-5 and IL-13) while SCIT was similar (whey) or increased (peanut). The authors 
addressed the frequency of CD4+CD69+ST2+ Th2, CD4+CD69+CXCR3+ Th1 and CD4+CD25+FoxP3+ 
regulatory T cells in spleen or mLN, however no clear allergen- or therapy-related patterns could be 
observed suggesting diverse underlying immunological mechanisms [15]. Other SCIT mouse models 
using food allergens support efficacy, but have been conducted without oral or IP allergen 
provocations for the assessment of clinical food allergy outcomes. Studies using ovalbumin or 
peanut SCIT found therapy to suppress allergen-specific IgE and increase IgG2a in serum [40,41]. In 
line, SCIT treated animals exhibited decreased airway hyperreactivity and suppressed type-2 
immune responses in the lung following airway allergen challenge. Additional mechanistic studies in 
SCIT models employing clinical food allergy-related outcomes are needed, including therapeutic 
duration, and adverse reactions compared to OIT. 
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Epicutaneous immunotherapy 
 Epicutaneus IT (EPIT) has recently emerged as a new mode of allergen delivery in food 
allergy therapy. It was hypothesized that applying allergen onto intact skin would allow controlled 
diffusion, and reduce risk of systemic allergen dissemination and anaphylaxis. To this end, DBV 
Technologies developed an epicutaneus delivery system (Viaskin patch) that consists of a chamber 
that releases allergen onto the skin [41], where it diffuses into the epidermis and is taken up by 
dendritic cells that migrates to draining lymph nodes and induce allergen-specific regulatory T cells 
[42]. Early studies found that EPIT could suppress allergen-specific IgE and type-2 immune 
responses, and increase allergen-specific IgG2a in ovalbumin [41,42], peanut [40,41], cow’s milk 
protein [43], house dust mite [41] and pollen [41,44] sensitized mice. The first studies of EPIT in 
relation to food allergy outcomes were conducted in models of esophago-gastro-enteropathy 
following long-term allergen exposure in sensitized animals. EPIT was found to completely reverse 
esophageal and gastric eosinophilia, and reduce serum allergen-specific IgE in peanut sensitized 
mice [45,46] and pigs [47]. Abrogated eosinophilia was associated with reduced eotaxin (CCL11) in 
mice esophagus and pig splenocytes. Furthermore, EPIT suppressed systemic allergen-specific type-2 
(IL-5 and IL-13) immune responses in the models. The studies in mice reported increased 
CD4+CD25+FoxP3+ regulatory T cells expressing CTLA-4, but not PD-1 or IL-10 in the spleen following 
EPIT [46]. The EPIT-induced regulatory T cells were found to suppress esophageal eosinophilia, 
eotaxin and IL-5 expression when adoptively transferred into non-treated peanut-sensitized animals. 
The regulatory T cells exhibited a stable phenotype as cells adoptively transferred from mice 8 weeks 
post-treatment retained the suppression of allergen-induced esophageal eosinophilia and systemic 
type-2 (IL-5 and IL-13) immune responses. These findings are supported by a more recent study 
demonstrating long-term stability of EPIT induced, but not OIT or sublingual IT (SLIT) induced, 
regulatory T cells [16]. EPIT-induced regulatory T cells were found to specifically express CCR9, CLA, 
CCR6, CCR3 and CCR8, suggesting that these cells can migrate and suppress allergic responses in 
several peripheral tissues, including the gut and skin. Interestingly, transfer of EPIT induced 
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regulatory T cells was found to expand the endogenous regulatory T cell population in recipient mice 
[46], which may explain why EPIT to cow’s milk proteins suppress later sensitization to peanut and 
house dust mite in mice [43]. 
 
A recent study reported the therapeutic involvement of EPIT-induced regulatory T 
cells in a model of acute ovalbumin-induced anaphylaxis [13]. In this study did EPIT, but not OIT, 
induce long-term (>5 weeks) protection against anaphylaxis following oral challenge in ovalbumin-
sensitized mice. Interestingly, humoral allergen-specific responses were not affected by treatment as 
demonstrated by basophil activation test and passive sensitization of naïve animal. Rather, allergen-
specific CD4+LAP+FoxP3- regulatory T cells expressing CCR9, CCR6 and CCR4 were found to be 
induced in response to EPIT, but not OIT. These cells were induced in skin-draining lymph nodes and 
migrated to mLN and gut lamina propria. Adoptive transfer and cytokine blocking experiments in 
passively sensitized mice indicated that EPIT-induced regulatory T cells suppress mast cell activation 
in a TGF-β dependent manner. 
 
The findings in EPIT models demonstrate that EPIT-induced regulatory T cells have a 
stable and distinct phenotype compared to regulatory T cells induced via other routes. Clinical trials 
in humans have shown that EPIT is safe, however the current strategies have demonstrated limited 
efficacy [48]. Further technical improvements of EPIT delivery, including skin preparation and 
delivery matrix, are open for optimization and mechanistic exploration in animal models of food 
allergy. 
 
Sublingual immunotherapy 
 Sublingual IT (SLIT) involves administration of allergen under the tongue followed by 
swallowing. This therapeutic route is commonly used in the treatment of allergic rhinitis and asthma 
with demonstrated efficacy in humans [49]. Clinical trials of SLIT in food allergy has been conducted 
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in humans, but indicated reduced efficacy in the treatment of peanut and cow’s milk allergy 
compared to OIT [50,51]. To our knowledge, only one therapeutic animal model using SLIT in 
relation to food allergy outcomes has been published. The study was published very recently 
demonstrating clinical efficacy of SLIT in cow’s milk sensitized mice using low dosages of allergen (pg 
to ng range) [52]. Therapy was associated with increased IL-10 and TGF-β levels in jejunum indicating 
a role of regulatory T cells. This is supported by the study mentioned earlier comparing the function 
and phenotype of regulatory T cells induced by SLIT, EPIT and OIT in peanut sensitized mice [53]. No 
marked therapeutic difference was observed between allergen administration routes in relation to 
increased allergen-specific IgG2a in serum and suppression of allergen-specific type-2 (IL-5 and IL-13) 
cytokines. SLIT and OIT did however increase allergen-specific IL-10 production compared to EPIT, 
which in the SLIT group was essential for the suppression of allergen-specific IL-5 and IL-13 ex vixo. 
These findings indicate that SLIT induces IL-10 producing regulatory Tr1 cells in this peanut model. 
The study further indicated that the SLIT-induced regulatory Tr1 cells were unstable, as regulatory T 
cells adoptively transferred 8 weeks post treatment to sensitized animals had lost the ability to 
suppress allergic esophageal eosinophilia and allergen-specific immune responses. Development of 
new SLIT food allergy animal models may further our understanding of the immunological 
mechanism of SLIT in this disease, and allow optimization of administration protocols and allergen 
formulation. 
 
Immunotherapy using immunomodulatory adjuvants 
 Adjuvants are commonly used in vaccines to elicit a desired immunological response.  
Therapeutic studies in food allergy models have explored the ability of adjuvants to skew the allergic 
type-2 immune response towards a type-1 response using TLR9 agonists [54–57] or heat-killed (HK) 
bacteria [58,59]. Two of the studies using TLR9 agonists were performed in mice sensitized to peanut 
using OIT [56] with whole peanut or peanut protein extract [54,55]. The studies addressing the role 
of HK bacterial adjuvants were performed using subcutaneous or per rectum (PR) IT using 
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recombinant Ara h 1-3 proteins with modified epitopes reducing IgE binding in peanut sensitized 
mice [58,59]. The studies reported similar results with suppression of oral challenge-induced 
anaphylaxis, reduced allergen-specific IgE and increased IgG2a in groups receiving adjuvant allergen-
specific therapy. Allergen-specific type-2 (IL-4, IL-5 and IL-13) immune responses were suppressed, 
whereas IFN-γ was increased. Similar results was obtained in a IPIT study in peanut sensitized mice 
comparing the action of class A, B, and C CpG-ODN TLR9 agonists, where therapeutic effect was 
reported for class B and C CpG-ODNs indicating that B cells are a target of TLR9 agonism [56]. Two 
studies performed several oral challenges indicating therapeutic efficacy for up to 10-16 weeks post 
treatment [55,59]. Combined, these findings indicate that Th1-driving adjuvants promote allergen-
specific Th1 cells with a stable phenotype. Another study using TLR9 agonist in intradermal IT in 
ovalbumin sensitized mice found limited effect on anaphylaxis scores and temperature loss, but 
indicated improved survival following challenge [57]. This finding may indicate allergen-specific 
differences, or reflect different treatment regimens. The role of regulatory T cells in these models 
remains largely unknown. One study using TLR9 agonist found no therapeutic effect on allergen-
specific TGF-β levels [55], whereas one model using HK bacterial reported increased allergen-specific 
TGF-β [59]. As HK bacteria contain several ligands stimulating innate immunity, it cannot be excluded 
that agonists targeting other pathogen-associated molecular pattern receptors than TLR9 can be 
involved in promoting regulatory T cells. Thus there is an opportunity to study the role of other 
adjuvants in these models to identify alternatives to complex whole bacterial adjuvants contain 
several unknown components and antigens. Additionally, targeting the gut microbiota composition 
using probiotics or prebiotics may be an option to modulate local immune responses. Administration 
of a mixture of probiotic bacteria to shrimp tropomyosin sensitized mice has previously been found 
to suppress type-2 immune responses and challenge-induced anaphylaxis [60]. Thus, combining 
probiotics and allergen-specific IT may lead to improved efficacy. 
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A recent study employed a synthetic cetylpyridinium chloride and oil based 
nanoemulsion adjuvant with type-1/17 driving properties for nasal peanut IT in mice [61]. The 
adjuvant was found to promote suppression of challenge-induced anaphylaxis, allergen-specific IgE, 
and type-2 (IL-4, IL-5, IL-33) immune responses, while increasing IgG2a and IgG2b and regulatory T 
cells. The induction of therapeutic efficacy was partly dependent on IL-10 highlighting an underlying 
role of immunoregulatory mechanisms in this type of adjuvant. The importance of enhancing 
immunoregulatory mechanisms during allergen-specific IT is further supported by a recent study 
combining SLIT and the expansion of regulatory T cells using IL-2/anti-IL-2Ab complexes in cow’s milk 
sensitized mice [52]. 
 
 An interesting study used peanut protein chemically coupled to syngeneic splenic 
leukocytes as intravenous (IV) IT in peanut sensitized mice [62]. The chemical linking induces 
apoptosis in leukocytes making the cells a therapeutic vehicle and adjuvant in allergen-specific IT. 
Previous studies suggest that the apoptotic leukocytes are taken up by splenic marginal zone APCs 
leading to the induction of clonal anergy and regulatory T cell specific for the coupled antigen. IT in 
peanut sensitized mice was found to reverse challenge-induced blood eosinophilia and suppress 
allergen-specific type-2 (IL-4 and IL-13) responses, but had only a week effect on anaphylactic scores. 
This IT approach may need optimization in terms of chemical linking, cell subsets, and control of 
apoptosis/necrosis. Other vehicles for allergen could be explored for IV administration, including 
synthetic particles, coupling to APC-receptor specific targets, and allergen complexes. 
 
Cellular immunotherapy 
IT using immune cells has been used in the clinic to promote anti-cancer immunity, 
commonly by administrating ex vivo expanded effector T cells or dendritic cells carrying cancer 
antigens [63]. To our knowledge, cellular IT has not been applied in clinical allergy, which likely is 
reflected by the very few studies of this therapeutic approach in food allergy animal models. The 
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generation and transfer of allergen-specific regulatory T cells could be a potential therapy. This was 
recently explored in a model of peanut allergy where mice received regulatory T cells from mice 
having received OIT, SLIT or EPIT with peanut [16]. The study found that EPIT-induced regulatory T 
cells could suppress the elicitation of esophageal eosinophilia. Although the main objective was to 
assess the phenotypic stability of regulatory T cells induced by various routes of IT, this study 
provides a model of exploring this type of IT. 
 
 Dendritic cells play a central role in instructing T cell responses based on molecular 
signals from pathogens and other environmental stimuli. A recent study exploited that retinoic acid 
stimulates the development of a tolerogenic dendritic cell phenotype (RA-DCs). RA-DCs was 
generated in vitro and pulsed with ovalbumin or peanut protein before being administrated IP to 
sensitized mice [64]. RA-DC therapy suppressed challenge-induced anaphylaxis and diarrhea in both 
models. Therapeutic efficacy was dependent on IL-27 production by the RA-DCs, and in vitro 
experiments found that RA-DCs stimulated the development of IL-10 producing regulatory 
CD4+LAG3+CD49b-FoxP3- Tr1 cells. Mechanistically the study indicated that the RA-DCs could 
suppress allergen-specific Th2 cells via IL-10 and TGF-β production, while IL-27 converted Th2 cells 
into regulatory Tr1 cells. 
 
 Cellular IT is in its infancy within food allergy, and inspiration could be taken from the 
experiences in the field of autoimmunity, which aims to suppress the pathological Th1/17 response 
and promote regulatory T cells [65]. Models using other immune cell phenotypes for therapy, as well 
as optimizing the approach in terms of cell preparation, route of delivery, and adjuvants may be 
needed. 
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Conclusion 
Animal models of food allergen-specific IT are widely used as a preclinical approach to 
study the efficacy of new therapeutic strategies. As reviewed here, animal models have been used as 
a first screen of the applicability of different routes of administration, the use of modified version of 
allergens, and the use of combining allergen with non-specific immune modulation. Efficacy has 
mostly been evaluated by means of anaphylactic scores, while the therapeutic mechanisms have 
primarily been associated of the induction of regulatory T cells, changes in allergen-specific antibody 
levels, and suppression of Th2-related cytokines. Only few of the reported studies use experimental 
techniques to ascertain causal therapeutic mechanisms, including the use of signal blocking, cell 
depletion and transfer experiments, and gene knock-out mice. Thus, there remain opportunities for 
in-depth mechanistic studies of the induction and maintenance of immunological tolerance in these 
models. As no allergen-specific immunotherapeutic approaches has yet been accepted in food 
allergy, animal models may play a valuable tool in addressing safety and efficacy, and to compare 
different approaches in a controlled environment. Animal models have the unique potential to allow 
the study of the efficacy of a given approach with different allergens, as well as the in-depth study of 
mechanisms underlying an immunotherapeutic effect. With the rising appreciation that food allergy 
is a heterogeneous disease [8] future models should include other disease-relevant clinical outcomes 
in addition to acute anaphylaxis, including diarrhea, respiratory function and gastrointestinal 
pathology. Intriguingly, the models presented underline a possible role of allergen-specific 
differences in therapeutic outcomes, mechanisms, and even sensitization. In line, the skin has been 
indicated as a route of sensitization for which models has recently been developed [13]. It remains 
however largely unknown how the route (oral, IP, skin, or respiratory) or method of sensitization 
(adjuvant use, or genetically susceptible mice) affect therapeutic outcomes in the presented IT 
models. Animal models will in the future remain a valuable tool to study efficacy and mechanisms in 
different food allergy phenotypes in a controlled manner. 
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Table 1 - Therapeutic animal models in food allergy 
Route Intervention 
Allergen 
(sensitization) Host Sensitization Treatment Challenge Outcomes Ref. 
 
Oral Immunotherapy (OIT)  
Oral Egg white Ovalbumin 
(Egg) 
Mouse; 
C3H/HeJ 
Oral; 1 mg 
ovalbumin + 10 µg 
CT weekly, 6 wks 
Increasing 1 – 
50 mg/day egg 
white for 14 
days 
Oral; 50 mg 
ovalbumin 
Short term amelioration of 
anaphylaxis (temperature 
loss) and disease score 
Clinical desensitization lost 
2wks post treatment 
Increased serum ovalbumin-
specific IgE and IgA, and 
similar IgG1 and IgG2a post-
treatment 
Suppression of splenic T cell 
cytokines  (IL-13, IL-10 and 
IFN-γ) 2 wks post-treatment 
Treatment induces increased 
gut permeability 
[12] 
Oral Egg white Ovomucoid 
(Egg) 
Mouse; 
C3H/HeJ 
Oral; 1 mg 
ovomucoid 
+ 10 µg CT weekly, 6 
wks 
Increasing 1 – 
50 mg/day egg 
white for 14 
days 
Oral; 25 mg 
ovomucoid  
Short term amelioration of 
anaphylaxis (temperature 
loss) and disease score 
Desensitization lost after 2 
wks post-treatment 
[12] 
Oral Native or heated 
ovomucoid 
 
Ovomucoid 
(Egg) 
Mouse; 
C3H/HeJ 
Oral; 1 mg 
ovomucoid + 10 µg 
CT weekly, 6 wks 
Increasing 0.5 
– 25 mg/day 
ovomucoid for 
14 days 
Oral; 25 mg 
ovomucoid 
Abrogation of anaphylaxis 
and disease score 
 
[12] 
Oral Ovalbumin Ovalbumin 
(Egg) 
Mouse; 
C3H/HeJ 
Skin; 100 µg 
ovalbumin weekly, 6 
wks  
1 mg 
ovalbumin, 
daily, 8 wks 
Oral; 10, 20, 
and 50 mg 
ovalbumin 
30 min apart 
Short term amelioration of 
anaphylaxis (temperature 
loss) 
Desensitization lost after 5 
wks post-treatment 
Increased serum IgG1 and 
IgG2a 
[13] 
Oral Ovalbumin Ovalbumin 
(Egg) 
Mouse; 
C3H/HeJ 
Oral; 1 mg 
ovalbumin + 10 µg 
CT weekly, 6 wks  
1 mg 
ovalbumin, 
daily, 8 wks 
Oral; 10, 20, 
and 50 mg 
ovalbumin 
30 min apart 
No effect on anaphylaxis 
(temperature loss) 
No effect on serum allergen-
specific IgG1 and IgG2a 
[13] 
Oral Cow milk protein Cow milk 
protein  
Mouse; 
BALB/c 
Oral; 20 mg cow milk 
protein + 10 CT 
weekly, 6 wks 
10 µg cow 
milk protein 
weekly, 4 or 8 
wks  
Oral; 10 mg 
cow milk 
protein 
Clinical scores ameliorated 
and negative skin test after 8 
wks of therapy 
Decreased serum allergen-
specific IgE and IgG1, but 
similar IgG2a 
[14] 
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Suppression of splenic  
allergen-specific cytokines IL-
5 and IL-13, but unchanged 
IFN-γ 
Reduced intestinal 
expression of IL-5, IL-13 and 
GATA3, and increased IFN-γ, 
IL-10, TGF-β and FoxP3 
Elevated percentages of 
intestinal CD4
+
CD25
+
FoxP3
+
 
cells expressing IL-10 
Oral Whey Whey (milk) Mouse; 
C3H/HeOuJ 
IG; 20 mg whey + 20 
µg CT; day 0, 7, 14, 
21 
and 28 
0.1, 1, 10 or 
100 mg whey 
5x weekly for 
3 wks 
50 mg IG,  
100 mg IP, 
or 10 µg ID; 
whey 
Decreased ear swelling, 
anaphylaxis score and 
temperature loss following ID 
challenge 
Decreased serum mMCP-1 
levels following IG challenge 
No protection from IP-
induced anaphylaxis 
Similar allergen-specific IgE, 
and increased IgG1 and IgG2a 
level in serum 
Reduced CD4
+
CD69
+
ST2
+
 Th2 
cells and increased 
CD4
+
CD69
+
CXCR3
+
 Th1 cells 
in spleen 
CD4
+
CD25
+
FoxP3
+
 regulatory 
T cells increased in mLN, but 
not spleen 
Suppressed allergen-specific 
IL-5 and IL-13, and similar IL-
10 and IFN-γ production by 
splenocytes 
[15] 
Oral Peanut butter; Anti-
IgE or SYKi facilitated 
Peanut butter  Mouse; 
allergy-
prone 
Il4raF709 
Oral; 23 mg peanut 
butter (5 mg 
protein) weekly, 4 
wks 
225 mg 
peanut butter 
daily, 3 wks; 
25 µg/day 
anti-IgE IP for 
4 days before 
peanut or 30 
mg/kg SYKi IG 
daily with the 
peanut 
Oral; 430 mg 
peanut 
butter 
Prolonged suppression of 
anaphylaxis 
Expansion of allergen-specific 
regulatory T cells 
Suppression of allergen-
specific Th2 immune 
responses 
 
[17] 
Oral Peanut protein 
extract 
Peanut 
protein 
Mouse; 
C3H/HeOuJ 
IG; 6 mg peanut 
protein extract + 20 
0.15, 1.5, or 
15 mg peanut 
15 mg IG, 
100 mg IP, 
Decreased ear swelling 
following ID challenge 
[15] 
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extract µg CT; day 0, 1, 2, 7, 
14, 21 and 28 
protein 
extract 5x 
weekly for 3 
wks 
or 1 µg ID; 
peanut 
protein 
extract 
Decreased serum mMCP-1 
levels following IG challenge 
Decreased  anaphylaxis score 
and temperature loss 
following IP-induced 
anaphylaxis 
Similar allergen-specific IgE, 
and increased IgG1 and IgG2a 
level in serum 
Similar CD4
+
CD69
+
ST2
+
 Th2 
cells, CD4
+
CD69
+
CXCR3
+
 Th1, 
and CD4
+
CD25
+
FoxP3
+
 
regulatory T cells in spleen 
Similar allergen-specific IL-5, 
IL-13, IL-10 and IFN-γ 
production by splenocytes 
Oral Peanut protein 
extract 
Peanut 
protein 
extract 
Mouse; 
BALB/c 
IG; 1 mg peanut 
protein extract + 10 
µg CT weekly for 6 
wks 
1 mg peanut 
protein 
extract week 
1, 2 mg 
protein week 
2, and 5 mg 
protein week 
3 - 8. 
None Suppression of allergen-
specific IgE and induction of 
IgG2a 
Reduced ex vivo splenic 
allergen-specific IL-5 and IL-
13, and increased IL-10  
Increased splenic  CD4
+
CD25
+
 
regulatory T cells expressing 
FoxP3, CTLA-4, LAP, CCR9 and 
CCR4 
[16] 
 
Intraperitoneal immunotherapy (IPIT) 
IP Cashew protein 
extract 
Cashew 
protein 
extract 
Mouse; 
C3H/HeJ 
Oral; 2 mg cashew 
protein extract + 10 
µg CT day 1, 8 and 
15, and 5 mg protein 
+ 10 µg CT day 22 
3 IP doses 
weekly; 
Dosing: 50 µg 
cashew 
protein 
extract week 
1, 125 µg 
week 2, and 
200 µg week 
3+4  
IP; 1 mg 
cashew 
protein 
extract 14 
days post 
treatment 
Abrogation of anaphylaxis 
(temperature loss) and 
disease score 
Increased allergen-specific 
IgG1 and IgG2a, but no effect 
on IgE 
Suppression of splenic  
allergen-specific cytokines IL-
5 and IL-13, but unchanged 
IL-4 and IFN-γ 
[21] 
IP 
 
 
 
Cashew protein 
extract in cross-
reactivity model 
Cashew or 
egg protein 
extract 
Mouse; 
C3H/HeJ 
IP; 500 µg protein 
extract (cashew or 
egg) +  2 mg alum 
week 1, 2 and 4 
3 IP doses 
weekly; 
Dosaging: 100 
µg protein 
extract 
(cashew) week 
1, 250 µg 
IP; 1 mg 
protein 
extract 
(cashew, 
pistachio, or 
egg) 
Abrogation of anaphylaxis 
(temperature loss) and 
disease score following 
cashew or pistachio 
challenge in  cashew-
sensitized mice 
Increased allergen-specific 
[22] 
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week 2, and 
500 µg week 
3+4 
IgG1 
Suppression of splenic  
allergen-specific cytokines IL-
4 and IL-5, and increased IL-
12p40 
Mice sensitized to egg was 
not protected from egg-
induced anaphylaxis 
following cashew IT 
IP Cashew or walnut 
protein extract in 
multi-sensitization 
model 
Cashew and 
walnut 
protein 
extract 
Mouse; 
C3H/Hej 
IP; 500 µg protein 
extract (cashew and 
walnut) +  2 mg alum 
week 1, 2, and 4 
3 IP doses 
weekly; 
Dosaging: 100 
µg protein 
extract 
(cashew 
and/or 
walnut) week 
1, 250 µg 
week 2, and 
500 µg week 
3+4 
IP; 1 mg 
protein 
(cashew, or 
walnut) 
Cashew and cashew + walnut 
IT protect from cashew-
induced anaphylaxis 
(temperature loss) and 
disease score 
Walnut IT partly protect from 
cashew-induced anaphylaxis 
(temperature loss) and 
disease score 
Walnut and cashew + walnut 
IT protect from walnut-
induced anaphylaxis 
(temperature loss) and 
disease score 
Cashew IT partly protect 
from walnut-induced 
anaphylaxis (temperature 
loss) and disease score 
Cashew, walnut and cashew 
+ walnut IT increases both 
cashew and walnut-specific 
IgG1 
[22] 
 
Immunotherapy using hydrolyzed food proteins 
IP Digested cashew 
protein extract 
Cashew 
protein 
extract 
Mouse; 
C3H/HeJ 
Oral; 2 mg cashew 
protein extract + 10 
µg CT day 1, 8 and 
15, and 5 mg protein 
+ 10 µg CT day 22 
3 IP doses pr. 
week; 
Dosaging: 50 
µg digested 
cashew 
protein 
extract week 
1, 125 µg 
week 2, and 
200 µg week 
3+4  
IP; 1 mg 
cashew 
protein 
extract 14 
days post 
treatment 
Abrogation of anaphylaxis 
(temperature loss) and 
disease score 
Increased allergen-specific 
IgG1 and IgG2a, but no effect 
on IgE 
Suppression of splenic  
allergen-specific cytokines IL-
5 and IL-13, but unchanged 
IL-4 and IFN-γ 
Clinical and immunological 
outcomes were similar in 
[21] 
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mice receiving therapy with 
intact cashew protein 
Oral Hydrolyzed egg 
white proteins 
Egg white 
proteins 
Mouse; 
BALB/c 
Oral; 5 mg egg white 
proteins + 10 µg CT 
2x weekly, 4 wks 
Oral; 5 mg 
hydrolyzed 
egg white 
proteins 3x 
weekly, 3 wks 
Oral; 20 mg 
egg white 
proteins 
Normalization of serum 
histamine 
Decreased allergen-specific 
IgE and IgG2a, and 
unchanged IgG and IgG1 
Reduced allergen-specific IL-4 
and IFN-γ by splenocytes 
Reduced intestinal 
expression of IL-4, IL-13, IFN-
γ, IL-10 and IL-12p40, and 
increased IL-18, IL-5, TGF-β 
and FoxP3 
[23] 
 
T cell directed peptide immunotherapy 
Oral Peptides from 
ovalbumin 
(immunodominat T 
cell epitopes) - 3 
single peptides or 
cocktail 
Ovalbumin 
(Egg) 
Mouse; 
BALB/c 
Oral; 1 mg 
ovalbumin + 10 µg 
CT 2x weekly, 4 wks 
Oral; 100 µg 
peptide 3x 
weekly, 3 wks 
Oral; 20 mg 
ovalbumin 
Peptide cocktail suppressed 
anaphylactic disease scores 
and serum histamine levels 
Reduced allergen-specific IgE 
and unchanged IgG 
Allergen-specific decreased 
IL-4 and increased IFN-γ in 
splenocytes 
Reduced intestinal 
expression of IL-4, IL-5, IL-13, 
and increased TGF-β and 
FoxP3 
Possibly increased fecal IgA 
[34] 
Oral Peptide from 
ovomucoid 
(immunodominat T 
cell epitope) - single 
or triple sequence 
Ovomucoid 
(Egg) 
Mouse; 
BALB/c 
Oral; 1 mg 
ovomucoid + 10 µg 
CT 2x weekly, 4 wks 
Oral; 1 mg 
single or 3 mg 
triple 3x 
weekly, 4 wks 
Oral; 20 mg 
ovomucoid 
Peptide abrogated disease 
score and histamine release 
Decreased allergen-specific 
IgE, similar IgG, IgG1 and 
increased IgG2a 
Possibly increased fecal IgA 
Allergen-specific decreased 
IL-4 and increased IL-12, IFN-
γand IL-10 in splenocytes 
Increase percentage of blood 
CD4
+
FoxP3
+
 cells 
[35] 
Oral Peptides from 
shrimp-tropomyosin 
(immunodominat T 
cell epitopes) - 
Cocktail of 6 
Recombinant 
shrimp-
tropomyosin 
Mouse; 
BALB/c 
Oral; 100 µg 
recombinant shrimp-
tropomyosin + 10 µg 
CT day 0, 12, 19, and 
26 
Oral; 1,2 mg 
peptide mix 2x 
weekly, 4 wks 
Oral; 500 µg 
recombinant 
shrimp-
tropomyosin 
Peptide cocktail suppressed 
disease scores, diarrhea, and 
serum mMCP-1 levels 
Decreased allergen-specific 
IgE, increased IgG2a and 
[28] 
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peptides similar IgG1 in serum 
Suppression of intestinal IL-5 
and IL-13 expression, and 
increased FoxP3, CD25, IL-10, 
IL-12, IL-18 and IFN-γ 
Allergen-specific decreased 
IL-4 and IL-5, and increased 
IFN-γ in splenocytes 
Oral Peptides from beta-
lactoglobulin 
(immunodominat T 
cell epitopes) - 2 
single peptides 
beta-
lactoglobulin 
(Milk) 
Mouse; 
BALB/c 
IP; 50 µg beta-
lactoglobulin + 2 mg 
alum weekly, 3 wks 
Oral; 1 mg 
peptide 3x 
weekly, 4 wks 
Oral; 50 mg 
beta-
lactoglobulin 
Peptides abrogation of 
anaphylaxis (temperature 
loss) and suppressed disease 
scores 
No effect on serum allergen-
specific IgE, IgG1, IgG2a, IgA, 
total-IgE, or fecal total-IgA 
No differences in allergen-
specific IFN-γ, IL-12, IL-4 
and/IL-10 in splenocytes or 
mLN cells 
No difference in splenic 
CD4
+
CD25
+
FoxP3
+
 regulatory 
T cell population 
[36] 
 
Subcutaneous immunotherapy (SCIT) 
SC Whey Whey (milk) Mouse; 
C3H/HeOuJ 
IG; 20 mg whey + 20 
µg CT; day 0, 7, 14, 
21, 
and 28 
SC; 2.5, 10 or 
25 μg whey 3x 
weekly, 3 wks  
 
50 mg IG, 
100 mg IP, 
or 10 µg ID; 
whey 
Decreased anaphylaxis score 
and temperature loss, but 
minimal effect on ear 
swelling following ID 
challenge 
Decreased serum mMCP-1 
levels following IG challenge 
No protection from IP-
induced anaphylaxis 
Increased allergen-specific 
IgE, IgG1, and IgG2a levels in 
serum 
Reduced CD4
+
CD69
+
ST2
+
 Th2 
cells and increased 
CD4
+
CD69
+
CXCR3
+
 Th1 cells 
in spleen 
Similar CD4
+
CD25
+
FoxP3
+
 
regulatory T cells in mLN and 
spleen 
Similar allergen-specific IL-5, 
IL-13, IL-10, and IFN-γ 
[15] 
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production by splenocytes 
SC Peanut protein 
extract 
Peanut 
protein 
extract 
Mouse; 
C3H/HeOuJ 
IG.; 6 mg peanut 
protein extract + 20 
µg CT; day 0, 1, 2, 7, 
14, 21, and 28 
SC; 1, 10 or 
100 µg peanut 
protein 
extract 3x 
weekly, 3 wks  
15 mg IG, 
100 mg IP, 
or 1 µg ID; 
peanut 
protein 
extract 
Minimal effect on ear 
swelling following ID 
challenge Decreased serum 
mMCP-1 levels following IG 
challenge 
Decreased  anaphylaxis score 
and temperature loss 
following IP-induced 
anaphylaxis 
Increased allergen-specific 
IgE, IgG1, and IgG2a levels in 
serum 
Increased CD4
+
CD69
+
ST2
+
 
Th2 cells, and similar 
CD4
+
CD69
+
CXCR3
+
 Th1, and 
CD4
+
CD25
+
FoxP3
+
 regulatory 
T cells in spleen 
Increased allergen-specific IL-
5 and IL-10, and similar IL-13 
and IFN-γ production by 
splenocytes 
[15] 
 
Epicutaneous immunotherapy (EPIT) 
EP Ovalbumin Ovalbumin 
(Egg) 
Mouse; 
C3H/HeJ 
Skin; 100 µg 
ovalbumin weekly, 6 
wks  
100 µg 
ovalbumin in 
Viaskin patch 
48 hours 
weekly, 8 wks 
Oral; 10, 20, 
and 50 mg 
ovalbumin 
30 min apart 
Long-term reversal  of 
anaphylaxis (temperature 
loss) at 1 and 5 weeks post-
treatment 
Persistent increased serum 
allergen-specific IgG1 and 
IgG2a at 1 and 5 weeks post-
treatment 
No effect in basophil 
activation tests 
No therapeutic blocking 
antibodies demonstrated by 
passive sensitization of naïve 
animal 
Therapeutic induction of 
CD4
+
LAP
+
FoxP3
-
 regulatory T 
cells in skin dLN and mLN 
expressing CCR9, CCR6 and 
CCR4 
Therapeutic effect mediate 
by TGF-β 
[13] 
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EP Ovalbumin Ovalbumin 
(Egg) 
Mouse; 
C3H/HeJ 
Oral; 1 mg 
ovalbumin + 10 µg 
CT weekly, 6 wks  
100 µg 
ovalbumin in 
Viaskin patch 
48 hours 
weekly, 8 wks 
Oral; 10, 20, 
and 50 mg 
ovalbumin 
30 min apart 
Reversal  of anaphylaxis 
(temperature loss) 
Increased allergen-specific 
IgG1 and IgG2a at 1 week, 
but not 5 weeks post 
treatment 
No effect in basophil 
activation tests 
No therapeutic blocking 
antibodies demonstrated by 
passive sensitization of naïve 
animal 
Therapeutic induction of 
CD4
+
LAP
+
FoxP3
-
 regulatory T 
cells in skin bLN and mLN 
expressing CCR9, CCR6 and 
CCR4 
Therapeutic effect mediate 
by TGF-β 
[13] 
EP Peanut protein 
extract 
Peanut 
protein 
extract 
Mouse; 
BALB/c 
Oral; 1 mg peanut 
protein extract + 10 
µg CT weekly, 6 wks 
100 µg peanut 
protein 
extract in 
Viaskin patch 
48 hours 
weekly, 8 wks 
Peanut as 
feed day 1-
4, peanut in 
feed day 5-
10, and 10 
mg IG daily 
the last 3 
days  
Suppression of esophageal 
eosinophilia, and acanthosis 
and inflammation scores 
Reversal of allergic 
enteropathy and villous 
morphology 
Increased IgG2a in serum 
Reduced allergen-specific IL-
5, IL-13 and IL-10, and similar 
IFN-γ production by 
splenocytes  
FoxP3 mRNA expression in 
esophagus 
Increased splenic 
CD4
+
CD25
+
FoxP3
+
 regulatory 
T cells expressing CTLA-4, but 
not IL-10 and PD-1 
Reduced eotaxin and 
increased FoxP3 expression 
in esophagus  
Efficacy dependent on CD25 
during treatment 
Long-term stability of 
treatment induced regulatory 
T cells was demonstrated by 
adoptive transfer of 
CD4
+
CD25
+
 T cells 8 wks post 
[45,46] 
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treatment 
EP Peanut protein 
extract 
Peanut 
protein 
extract 
Pig; (LW  x 
LR) x P 
IP; 100 µg peanut 
protein extract + 8 
mg alum week 1, 2, 
and 4 
100 µg peanut 
protein 
extract in 
Viaskin patch 
for 24 hours 
daily, 81 days 
Oral; 4 mg 
peanut 
protein 
extract daily 
for 10 days 
Reversal of visual gastritis, 
and gastric tissue 
inflammation and 
eosinophilia 
Reduced serum allergen-
specific IgE 
Suppression of splenic Gata3, 
FoxP3, IL-5 and eotaxin 
mRNA expression 
[47] 
 
Sublingual immunotherapy (SLIT) 
SL Cow milk protein Cow milk 
protein 
Mouse; 
BALB/c 
IG; 20 mg cow milk 
protein + 10 µg CT 
weekly, 6 wks 
10 pg 2x 
weekly, 4 
weeks. 
Followed by 
10 ng 2x 
weekly, 4 
weeks; cow 
milk protein 
IG; 10 mg 
cow milk 
protein 
twice 24h 
apart 
Suppression of clinical 
symptom scores  
Decreased allergen-specific 
serum IgE 
Decreased allergen-specific 
IL-5 production by 
splenocytes 
Increased IL-10 and TGF-β 
levels in jejunum 
[52] 
 
Immunotherapy using immunomodulatory adjuvants 
Oral TLR9 agonist (IMO) + 
peanut protein 
extract 
Peanut 
protein 
extract 
Mouse; 
C3H/HeJ 
Oral; 1 mg peanut 
protein extract + 10 
µg CT day 0 and 14. 
1 mg peanut 
protein 
extract with or 
without 150 
µg TLR9 
agonist day 
21, 24, 28, and 
31 
IG; 1 mg 
peanut 
protein 
extract 2x, 
30-40 min 
interval 
Suppression of anaphylaxis 
scores and reversal of serum 
histamine levels 
Reduced mast cells and 
eosinophils in small intestine 
Decreased in allergen-specific 
IgE and IgG1, and increased 
IgG2a in serum 
Increased allergen-specific 
IgA in intestine 
Suppressed allergen-specific 
IL-5 and IL-13, and increased 
IFN-γ production by 
splenocytes 
[54] 
IG TLR9 agonist (class B 
CpG-ODN 1826) + 
defatted whole 
roasted peanut in 
PLGA nanoparticles 
Whole 
roasted 
peanut 
Mouse; 
C3H/HeJ 
IG; 10 mg whole 
roasted peanut + 20 
µg CT + 1.1 µl 80-
proof EtOH pr. g BW 
weekly, 6 wks. 50 
mg boost with same 
adjuvant wks 7 and 8 
200 µg whole 
roasted 
peanut with or 
without 1.8 µg 
TLR9 agonist 
weekly, 4 wks 
Oral; 200 mg 
whole 
roasted 
peanut 
(done 
weekly with 
IG 
sensitization 
Suppression of anaphylaxis 
scores, temperature loss and 
plasma histamine levels 
Decrease in allergen-specific 
IgE and IgG1, and increased 
IgG2a in serum 
Decreased allergen-specific 
IL-4, IL-5 and IL-13, and 
[55] 
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dose the day 
after for 5 
wks) 
increased IFN-γ production 
by splenocytes 
 IP TLR9 agonist (class A 
CpG-ODN 1585, class 
B CpG-ODN 1826, or 
class C CpG-ODN 
M362) + peanut 
protein extract  
Peanut 
protein 
extract 
Mouse; 
C3H/HeJ 
IP; 500 µg peanut 
protein extract + 2 
mg alum weekly, 3 
wks 
Increasing 100 
– 500 µg 
peanut 
protein 
extract with or 
without 30 µg 
TLR9 agonist 
twice weekly, 
3 wks 
IP;  1 mg 
peanut 
protein 
extract 
Class B and C CpG-ODNs 
decreased anaphylaxis 
scores, temperature loss and 
serum MMCP-1 levels 
Similar allergen-specific IgE 
and IgG1, and increased 
IgG2a in serum 
Decreased allergen-specific 
IL-5 and IL-13, and similar IL-
4 production by splenocytes 
Class B CpG-ODN increased 
allergen-specific IFN-γ 
production by splenocytes 
[56] 
ID TLR9 agonist (class B 
CpG-ODN 1826) + 
ovalbumin in PLGA 
nanoparticles 
Ovalbumin 
(Egg) 
Mouse; 
BALB/c 
IP; 50 µg ovalbumin 
+ 2 mg alum weekly, 
2 wks 
20 µg 
ovalbumin 
with or 
without 25 µg 
TLR9 agonist, 
3x 6 days 
apart 
IP; 1 mg 
ovalbumin 
Limited effect on anaphylaxis 
score and temperature loss 
Possible protection from 
death 
 
[57] 
SC Heat-killed Listeria 
monocytogenes 
(HKLM) + IgE-binding 
modified 
recombinant Ara h 1-
3 
Whole 
roasted 
peanut 
Mouse; 
C3H/HeJ 
IG; 10 mg whole 
roasted peanut + 20 
µg CT + 1, weekly, 
week 1-6 and 8 
90 ug 
modified 
recombinant 
Ara h 1-3 with 
10
8
 HKLM 
weekly, 3 wks, 
or without 
HKLM 3x 
weekly, 4 wks 
IG; 25 mg 
whole 
roasted 
peanut 2x, 
30 - 40 min 
interval 
Suppression plasma 
histamine levels, but limited 
effect on of anaphylaxis 
scores and temperature loss 
Limited effect on respiratory 
distress measured as 
unrestrained Peak Expiratory 
Flow  
Decreased allergen-specific 
IgE and increased IgG2a in 
serum 
Decreased allergen-specific 
IL-4, IL-5 and IL-13, and 
increased IFN-γ production 
by splenocytes 
[58] 
PR Heat-killed 
Escherichia coli 
expressing IgE-
binding modified 
recombinant Ara h 1-
3 
Whole 
roasted 
peanut 
Mouse; 
C3H/HeJ 
IG; 10 mg whole 
roasted peanut + 20 
µg CT + 1, weekly, 
week 1-6 and 8 
0,9, 9 or 90 µg 
whole roasted 
peanut 
weekly, 3 wks 
IG; 25 mg 
whole 
roasted 
peanut 2x, 
30-40 min 
interval at 2, 
6 and 10 
Long-term reversal of 
anaphylaxis scores and 
suppression of plasma 
histamine levels 
Decreased allergen-specific 
IgE and increased IgG2a in 
serum 
[59] 
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wks post-
treatment 
Decreased allergen-specific 
IL-4, IL-5 and IL-13, and 
increased IFN-γ and TGF-β 
production by splenocytes 
 
 IN Nanoemulsion 
(cetylpyridinium 
chloride and oil 
based) + peanut 
protein extract 
Peanut 
protein 
extract 
Mouse; 
C3H/HeJ 
IP; 20 µg peanut 
protein extract + 2 
mg alum, weekly, 2 
wks 
20 µg peanut 
protein 
extract with or 
without 20 % 
nanoemulsion, 
3x, 4 wks 
apart 
IG; 10 mg 
peanut 
flour, 6x 
during 2 wks 
(or 100 µg 
IP)  
Suppression of anaphylaxis 
scores and temperature loss 
following IP challenge 
Suppression of anaphylaxis 
scores and serum MCPT-1 
levels following IG challenge 
Decreased allergen-specific 
IgE and IgG1, and increased 
IgG2a and IgG2b 
Decreased allergen-specific 
IL-4, IL-13, IL-33 and IL-21, 
and increased IFN-γ, IL-22, 
and IL-10 in mLN cells 
Increased percentage of 
CD4+CD25+FoxP3 regulatory 
T cells in mLN 
Induction of therapeutic 
efficacy was partly 
dependent on IL-10 
[61] 
 Nanoemulsion 
(cetylpyridinium 
chloride and oil 
based) + peanut 
protein extract 
Peanut 
protein 
extract 
Mouse; 
C3H/HeJ 
IG; 1 mg peanut 
protein extract + 10 
µg CT, 3x weekly, 2 
wks 
20 µg peanut 
protein 
extract with or 
without 20 % 
nanoemulsion, 
3x, 4 wks 
apart 
IG; 10 mg 
peanut 
flour, 6x 
during 2 wks 
(or 100 µg 
IP) 
Suppression of anaphylaxis 
scores and serum MCPT-1 
levels following IG challenge 
Decreased allergen-specific 
IL-4, and IL-13, and increased 
IFN-γ and IL-10 in mLN cells 
[61] 
SL IL-2/anti-IL-2Ab 
complex (IL-2C) + 
cow milk protein 
Cow milk 
protein 
Mouse; 
BALB/c 
IG; 20 mg cow milk 
protein + 10 µg CT 
weekly, 6 wks 
10 pg cow 
milk protein 
2x weekly, 4 
weeks. 
Followed by 
10 ng cow 
milk protein 
2x weekly, 4 
weeks. With 
or without IL-
2C (15000IU 
IL-2 + 4.5 µg 
anti-IL-2) IP 5x 
in the 
IG; 10 mg 
cow milk 
protein 
twice 24h 
apart 
Possibly enhanced SLIT 
therapy indicated by weak 
suppression of clinical 
symptom scores and 
allergen-specific serum IgE 
Expansion of intestinal 
mucosal CD4+CD25+FoxP3+ 
regulatory T cells 
Increased TGF-β levels in 
jejunum  
 
[52] 
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treatment 
period 
 IV Peanut protein 
extract fixed to 
splenic leukocytes 
Peanut 
protein 
extract 
Mouse; 
C3H/HeJ 
IG; 100 µg peanut 
protein extract + 50 
µg SEB, weekly, 8 
wks 
5 x 10
7
  
leukocytes, 
weekly, 2 wks 
Oral; 5 mg 
peanut 
protein 
extract 
Weak effect on anaphylaxis 
scores, but reversed blood 
eosinophilia 
Similar allergen-specific IgE  
Decreased allergen-specific 
IL-4 and IL-13, and similar IL-
5 production by splenocytes 
[62] 
 
Cellular immunotherapy 
IV CD4+CD25+ 
regulatory T cells 
induced by OIT, SLIT 
or EPIT 
Peanut 
protein 
extract 
Mouse; 
BALB/c 
IG; 1 mg peanut 
protein extract + 10 
µg CT weekly for 6 
wks 
5 x 10
5
 Treg 
cells 
Peanut as 
feed day 1-
4, peanut in 
feed day 5-
10, and 10 
mg peanut 
protein 
extract IG 
daily the last 
3 days 
EPIT-induced CD4
+
CD25
+
 
Tregs suppressed of 
esophageal eosinophilia 
Suppressed allergen-specific 
IL-5, IL-13, IFN-γ and IL-10 
production by splenocytes 
 
[16] 
IP Ovalbumin-pulsed 
retinoic acid-
differentiated 
dendritic cells (RA-
DCs) generated in 
vitro 
Ovalbumin 
(Egg) 
Mouse; 
BALB/c 
IP; 2 µg ovalbumin + 
2 mg alum 
10
6
 RA-DCs IG; 2 mg 
ovalbumin 
Suppression of anaphylaxis 
score, diarrhea incidence, 
and serum mMCP-1 
Decreased serum allergen-
specific IgE and IgG1 
Decreased IL-4, IL-5, IL-9 and 
IL-13 in peritoneal fluid  
Therapeutic effect 
dependent on IL-27 
production by RA-DCs 
[64] 
IP Peanut protein-
pulsed retinoic acid-
differentiated 
dendritic cells (RA-
DCs) generated in 
vitro 
Peanut 
protein 
extract 
Mouse; 
BALB/c 
IP; 20 µg peanut 
protein extract + 1 
mg alum 
10
6
 RA-DCs IG; 50 mg 
peanut 
butter 
Suppression of anaphylaxis 
score, diarrhea incidence, 
and serum mMCP-1 
Decreased serum allergen-
specific IgE and IgG1 
Similar IL-4, IL-5, IL-9 and IL-
13, and increased IL-10 in 
peritoneal fluid  
[64] 
CMP, Cow’s milk protein; CT, Cholera toxin; dNL, Draining lymph node; EP, Epicutaneous; EPIT, Epicutaneous Immunotherapy; HK, Heat-killed; ID, Intradermal; IN, Intranasal; IG, Intragastric; IP, Intraperitoneal; IPIT, 
Intraperitoneal Immunotherapy; IT, Immunotherapy; IV, Intravenous; mLN, Mesenteric lymph node; PR, Per rectum; SC, Subcutaneous; SCIT, Subcutaneous immunotherapy; SL, Sublingual; SLIT, Sublingual IT; Treg, 
Regulatory T cell. 
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Figure legends 
 
Figure 1 – Overview of allergen-specific immunotherapy models in food allergy. Flowcharts show 
models in relation to a particular food allergy (egg, cow’s milk, peanut, tree nut, and shrimp) with 
the specific allergen, mode of sensitization, and therapy used. The thickness of lines shows the 
number of models reported using the specific approach (1-8). Immunotherapeutic approaches 
include oral (OIT), intraperitoneal (IPIT), subcutaneous (SCIT), epicutaneous (EPIT), or sublingual 
(SLIT) administration of allergen, allergen in combination with immunomodulatory adjuvant 
(adjuvant IT) or immune cells (cellular IT), and preparations of hydrolyzed allergen or allergen-
derived T cell epitopes. Unless stated otherwise the reported models were conducted in mice. 
Il4raF709 designate that the model was conducted in allergy-prone mice with gain-of-function 
mutation in the IL-4 receptor α chain.  
 
Figure 2 – Overview of clinical and immunological outcomes assessed within allergen-specific 
immunotherapy models in food allergy. Outcomes has been divided into clinical (symptoms), para-
clinical (histology), and immunological (serology, systemic and tissue immune responses) measures. 
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